Betaxolol

产品说明书

Print
Chemical Structure| 63659-18-7 同义名 : -
CAS号 : 63659-18-7
货号 : A140706
分子式 : C18H29NO3
纯度 : 95%
分子量 : 307.43
MDL号 : MFCD00242958
存储条件：

Pure form Keep in dark place, sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(341.54 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • β-adrenergic receptor
描述 Betaxolol, a highly selective beta(1)-adrenergic receptor antagonist, could ameliorate cocaine withdrawal-induced anxiety[3]. in vivo, Betaxolol has therapeutic effects in reducing anxiety in patients with persistent anxiety disorders. The efficacy of Betaxolol (5mg/kg) in producing anxiolysis during early cocaine withdrawal is potentially related to its effect on β1-adrenergic receptors in the amygdala which are up-regulated during this time period[3]. Moreover, betaxolol has efficacy in reducing intraocular pressure (IOP). Betaxolol may be relatively safer to use in patients with reactive airway disease[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01316952 - Completed - -
NCT00684489 Hypertension Not Applicable Completed - -
NCT00000132 Open-Angle Glaucoma Phase 3 Unknown - Sweden ... 展开 >> Department of Ophthalmology, Helsingborg Hospital Helsingborg, Sweden Department of Ophthalmology, Malmo University Hospital, University of Lund Malmo, Sweden 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.25mL

0.65mL

0.33mL

16.26mL

3.25mL

1.63mL

32.53mL

6.51mL

3.25mL
参考文献

[1]Rudoy CA, Van Bockstaele EJ. Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29.

[2]Lesar TS. Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63.

[3]Rudoy CA, Van Bockstaele EJ. Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29.

[4]Lesar TS. Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63.